|
Supplemental financial information (Tables)
|
12 Months Ended |
|
Dec. 31, 2013
|
| Accounting Policies [Abstract] |
|
| Schedule of Inventory |
Inventories at December 31, 2012 and December 31, 2013, consisted of the following: | | | | | | | | | (Dollars in thousands) | December 31,
2012 | | December 31,
2013 | Raw materials | $ | 1,032 |
| | $ | 1,658 |
| Work in process | 145 |
| | 547 |
| Finished goods | 1,204 |
| | 1,679 |
| Total | $ | 2,381 |
| | $ | 3,884 |
|
|
| Schedule of Property and equipment |
Property and equipment at December 31, 2012 and December 31, 2013, consisted of the following: | | | | | | | | | (Dollars in thousands) | December 31,
2012 | | December 31,
2013 | Leasehold improvements | $ | 438 |
| | $ | 451 |
| Production and lab equipment | 3,852 |
| | 4,815 |
| Office and computer equipment | 475 |
| | 546 |
| Construction-in-progress | — |
| | 932 |
| | 4,765 |
| | 6,744 |
| Less accumulated depreciation and amortization | (3,892 | ) | | (4,692 | ) | Total | $ | 873 |
| | $ | 2,052 |
|
|
| Schedule of Accrued liabilities |
Accrued liabilities at December 31, 2012 and December 31, 2013, consisted of the following: | | | | | | | | | (Dollars in thousands) | December 31,
2012 | | December 31,
2013 | Accrued payroll, vacation and employee-related expenses | $ | 741 |
| | $ | 1,024 |
| Accrued incentive compensation | — |
| | 1,229 |
| Accrued unbilled professional fees | 315 |
| | 196 |
| Accrued royalties | 500 |
| | 584 |
| Accrued quarterly consulting fees | 76 |
| | 76 |
| Accrued incentives for sales staff | 128 |
| | 202 |
| Other | 70 |
| | 50 |
| Total | $ | 1,830 |
| | $ | 3,361 |
|
|
| Schedule of common shares that were excluded from diluted net loss per share |
For purposes of this calculation, the following potential common shares were excluded because including them would have been anti-dilutive: | | | | | | | | | | | | | December 31, | | | 2011 | | 2012 | | 2013 | Preferred series A | | 2,914,187 |
| | 2,914,187 |
| | — |
| Preferred series B | | 5,572,000 |
| | 7,232,092 |
| | — |
| Common stock warrants | | 8,208 |
| | 8,208 |
| | 28,406 |
| Common stock options | | 1,545,938 |
| | 1,617,875 |
| | 2,388,394 |
| | | 10,040,333 |
| | 11,772,362 |
| | 2,416,800 |
|
|
| Schedule of revenue by product |
Product information – The following table provides Product sales revenue by product: | | | | | | | | | | | | | Year ended | | | December 31, | (Dollars in thousands) | | 2011 | | 2012 | | 2013 | iCell Cardiomyocytes | | $1,350 | | $2,610 | | $4,787 | iCell Neurons | | 45 |
| | 2,256 |
| | 2,428 |
| MyCell | | — |
| | — |
| | 222 |
| Other | | 65 |
| | 312 |
| | 561 |
| Total | | $1,460 | | $5,178 | | $7,998 |
|
| Schedule of revenue by geographic region |
Geographical information – The following table provides percentage of total revenues by region, based on shipping locations: | | | | | | | | | | | | | Year ended | | | December 31, | | | 2011 | | 2012 | | 2013 | United States of America | | 74 | % | | 66 | % | | 56 | % | Europe | | 17 | % | | 24 | % | | 38 | % | Japan | | 8 | % | | 5 | % | | 5 | % | Other | | 1 | % | | 5 | % | | 1 | % | Total | | 100 | % | | 100 | % | | 100 | % |
|